Ginkgo Bioworks Holdings, Inc. (DNA) Declines More Than Market: Some Information for Investors

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.31, reflecting a -1.27% change from the previous day, underperforming the S&P 500 which had a daily loss of 0.13% [1] - Over the last month, the company's shares increased by 13.48%, outperforming the Medical sector's decline of 2.41% and the S&P 500's gain of 0.78% [1] Earnings Estimates - The upcoming earnings release is anticipated, with an expected EPS of -$1.8, indicating a 1.1% growth compared to the same quarter last year [2] - Revenue is projected at $37 million, reflecting a 15.62% decrease from the equivalent quarter last year [2] - For the full year, earnings are estimated at -$5.94 per share and revenue at $173 million, showing a 42.66% increase in earnings but no change in revenue from the previous year [3] Analyst Sentiment - Recent changes to analyst estimates are crucial for investors, as they reflect short-term business trends and can indicate analyst optimism regarding profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Ginkgo Bioworks Holdings, Inc. at 3 (Hold) [5] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]